Pancreatic Cancer Research

ResearcherJiangnan UniversityActive in the last 2 years

Ge Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1224-1413; OpenAlex author ID A5013962838. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 9

  1. HPGDS as a biomarker for prognosis and immunotherapy in pancreatic cancer Co-author DOI 10.21203/rs.3.rs-6637568/v1↗
  2. Development of a Serum-Based MicroRNA Signature for Early Detection of Pancreatic Cancer: A Multicenter Cohort Study. First author DOI 10.1007/s10620-024-08338-4↗
  3. LncRNA SNHG6 Upregulates KPNA5 to Overcome Gemcitabine Resistance in Pancreatic Cancer via Sponging miR-944. Co-author DOI 10.3390/ph16020184↗
  4. Pancreatitis initiated pancreatic ductal adenocarcinoma: Pathophysiology explaining clinical evidence. Co-author DOI 10.1016/j.phrs.2021.105595↗
  5. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal. Co-author DOI 10.1097/mpa.0000000000001920↗
  6. CYP2J2-produced epoxyeicosatrienoic acids contribute to the ferroptosis resistance of pancreatic ductal adenocarcinoma in a PPARγ-dependent manner. Last author DOI 10.11817/j.issn.1672-7347.2021.210413↗
  7. Inhibition of LONP1 protects against erastin-induced ferroptosis in Pancreatic ductal adenocarcinoma PANC1 cells. Last author DOI 10.1016/j.bbrc.2019.11.187↗
  8. Inhibition of LONP1 Suppresses Pancreatic Cancer Progression Via c-Jun N-Terminal Kinase Pathway-Meditated Epithelial-Mesenchymal Transition. Last author DOI 10.1097/mpa.0000000000001321↗
  9. [MicroRNA-21 correlates TGF-β1 pathway of pancreatic ductal adenocarcinoma]. Last author DOI 10.11817/j.issn.1672-7347.2019.180708↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gary Guishan Xiao · 4 shared papers, 2019–2024 · strength 0.53
  2. Hai Wang · 3 shared papers, 2019–2021 · strength 0.39
  3. Junchao Guo · 2 shared papers, 2021–2024 · strength 0.31
  4. Jianzhou Liu · 2 shared papers, 2021–2024 · strength 0.29
  5. Vay Liang W. Go · 2 shared papers, 2021–2024 · strength 0.29
  6. Yue Pan · 2 shared papers, 2021 · strength 0.27
  7. Xufeng Tao · 2 shared papers, 2021 · strength 0.27
  8. Junjing Zhou · 1 shared paper, 2025 · strength 0.25
  9. Hao Ye · 1 shared paper, 2025 · strength 0.25
  10. Xiang Wu · 2 shared papers, 2019 · strength 0.23
  11. Can Liu · 2 shared papers, 2019–2020 · strength 0.20
  12. Yong Zhou · 2 shared papers, 2019–2020 · strength 0.20
  13. Xiao Jun Zhou · 1 shared paper, 2023 · strength 0.19
  14. Pengzuo Tao · 1 shared paper, 2021 · strength 0.19
  15. Zhigang Zhang · 1 shared paper, 2024 · strength 0.16
  16. Yefu Liu · 1 shared paper, 2024 · strength 0.16
  17. Yongwei Sun · 1 shared paper, 2024 · strength 0.16
  18. Jing Li Huang · 1 shared paper, 2024 · strength 0.16
  19. Minwei Yang · 1 shared paper, 2024 · strength 0.16
  20. Dong Shang · 1 shared paper, 2024 · strength 0.16
  21. Hong Xiang · 1 shared paper, 2021 · strength 0.15
  22. Dong Shang · 1 shared paper, 2021 · strength 0.15
  23. Junchao Guo · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.